Glibornuride | KATP channels blocker | CAS#26944-48-9

MedKoo Cat#: 526037 | Name: Glibornuride

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Glibornuride is a blocker of adenosine 5'-triphosphate (ATP)-sensitive K+ channels (KATP channels).

Chemical Structure

Glibornuride

CAS#26944-48-9

Theoretical Analysis

MedKoo Cat#: 526037

Name: Glibornuride

CAS#: 26944-48-9

Chemical Formula: C18H26N2O4S

Exact Mass: 366.1613

Molecular Weight: 366.48

Elemental Analysis: C, 58.99; H, 7.15; N, 7.64; O, 17.46; S, 8.75

Price and Availability

Size	Price	Availability
25mg	USD 750.00	2 Weeks
50mg	USD 1,250.00	2 Weeks
1g	USD 5,650.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

Glibornuride; Glibornurida; Glutril; Glibornuridum; Gluboride; Ro 6-4563; Ro6-4563; Ro-6-4563; Ro-64563

IUPAC/Chemical Name

1-[(1S,2S,3R,4R)-3-hydroxy-4,7,7-trimethyl-2-bicyclo[2.2.1]heptanyl]-3-(4-methylphenyl)sulfonylurea

InChi Key

RMTYNAPTNBJHQI-LLDVTBCESA-N

InChi Code

InChI=1S/C18H26N2O4S/c1-11-5-7-12(8-6-11)25(23,24)20-16(22)19-14-13-9-10-18(4,15(14)21)17(13,2)3/h5-8,13-15,21H,9-10H2,1-4H3,(H2,19,20,22)/t13-,14+,15+,18+/m1/s1

SMILES Code

O=C(NS(=O)(C1=CC=C(C)C=C1)=O)N[C@H]2[C@@](C3(C)C)([H])CC[C@@]3(C)[C@H]2O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Product Data

Product Data

Instruction

View handling instruction

Biological target:

Glibornuride is a blocker of ATP-sensitive K+ channels (KATP channel) with a pKi of 5.75.

In vitro activity:

TBD

In vivo activity:

In contrast, in the STZ (streptozotocin)-diabetic group given glibornuride blood glucose levels, serum aspartate transaminase activity and total lipid levels decreased and blood glutathione levels increased. Significant changes in total protein levels in the serum were not observed in any group. As a conclusion, this study can say that glibornuride has a protective effect against the hepatotoxicity produced by STZ-diabetes. Reference: Hum Exp Toxicol. 2004 May;23(5):257-64. https://pubmed.ncbi.nlm.nih.gov/15228018/

	Solvent	mg/mL	mM
Solubility
	DMSO	250.0	682.17

Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 366.48 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

1. Bolkent S, Yanardağ R, Karabulut-Bulan O, Ozsoy-Saçan O. The morphological and biochemical effects of glibornuride on rat liver in experimental diabetes. Hum Exp Toxicol. 2004 May;23(5):257-64. doi: 10.1191/0960327104ht444oa. PMID: 15228018.

In vitro protocol:

TBD

In vivo protocol:

1: Binz TM, Villani N, Neels H, Schneider S. Rapid extraction, identification and quantification of oral hypoglycaemic drugs in serum and hair using LC-MS/MS. Forensic Sci Int. 2012 Nov 30;223(1-3):119-24. doi: 10.1016/j.forsciint.2012.08.014. Epub 2012 Aug 30. PubMed PMID: 22940189. 2: Hess C, Musshoff F, Madea B. Simultaneous identification and validated quantification of 11 oral hypoglycaemic drugs in plasma by electrospray ionisation liquid chromatography-mass spectrometry. Anal Bioanal Chem. 2011 Apr;400(1):33-41. doi: 10.1007/s00216-011-4698-8. Epub 2011 Feb 17. PubMed PMID: 21327875. 3: Yarat A, Yanardağ R, Tunali T, Sacan O, Gursoy F, Emekli N, Ustuner A, Ergenekon G. Effects of glibornuride versus metformin on eye lenses and skin in experimental diabetes. Arzneimittelforschung. 2006;56(7):541-6. PubMed PMID: 16927537. 4: Ozsoy-Sacan O, Yanardag R, Orak H, Ozgey Y, Yarat A, Tunali T. Effects of parsley (Petroselinum crispum) extract versus glibornuride on the liver of streptozotocin-induced diabetic rats. J Ethnopharmacol. 2006 Mar 8;104(1-2):175-81. Epub 2005 Oct 11. PubMed PMID: 16223573. 5: Hoizey G, Lamiable D, Trenque T, Robinet A, Binet L, Kaltenbach ML, Havet S, Millart H. Identification and quantification of 8 sulfonylureas with clinical toxicology interest by liquid chromatography-ion-trap tandem mass spectrometry and library searching. Clin Chem. 2005 Sep;51(9):1666-72. Epub 2005 Jul 14. PubMed PMID: 16020498. 6: Bolkent S, Yanardağ R, Karabulut-Bulan O, Ozsoy-Saçan O. The morphological and biochemical effects of glibornuride on rat liver in experimental diabetes. Hum Exp Toxicol. 2004 May;23(5):257-64. PubMed PMID: 15228018. 7: Maurer HH, Kratzsch C, Kraemer T, Peters FT, Weber AA. Screening, library-assisted identification and validated quantification of oral antidiabetics of the sulfonylurea-type in plasma by atmospheric pressure chemical ionization liquid chromatography-mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2002 Jun 15;773(1):63-73. PubMed PMID: 12015271. 8: Stahl M, Berger W. Higher incidence of severe hypoglycaemia leading to hospital admission in Type 2 diabetic patients treated with long-acting versus short-acting sulphonylureas. Diabet Med. 1999 Jul;16(7):586-90. PubMed PMID: 10445835. 9: Cakir B, Ayavaz G, Cakir N, Arslan M. The Effect of Glibornuride on Plasma Atrial Natriuretic Factor Levels in Patients with Newly Diagnosed NIDDM. Endocr Regul. 1998 Mar;32(1):27-31. PubMed PMID: 10407367. 10: Gros L, Virsolvy A, Salazar G, Bataille D, Blache P. Characterization of low-affinity binding sites for glibenclamide on the Kir6.2 subunit of the beta-cell KATP channel. Biochem Biophys Res Commun. 1999 Apr 21;257(3):766-70. PubMed PMID: 10208857. 11: Löffler-Walz C, Quast U. Binding of K(ATP) channel modulators in rat cardiac membranes. Br J Pharmacol. 1998 Apr;123(7):1395-402. PubMed PMID: 9579735; PubMed Central PMCID: PMC1565308. 12: Metzger F, Löffler C, Quast U. Sulphonylurea binding in rat isolated glomeruli: pharmacological characterization and dependence on cell metabolism and cytoskeleton. Naunyn Schmiedebergs Arch Pharmacol. 1997 Feb;355(2):141-9. PubMed PMID: 9050005. 13: Löffler C, Quast U. Pharmacological characterization of the sulphonylurea receptor in rat isolated aorta. Br J Pharmacol. 1997 Feb;120(3):476-80. PubMed PMID: 9031752; PubMed Central PMCID: PMC1564480. 14: Nielsen-Kudsk JE. Potassium channel modulation: a new drug principle for regulation of smooth muscle contractility. Studies on isolated airways and arteries. Dan Med Bull. 1996 Dec;43(5):429-47. PubMed PMID: 8960816. 15: Selvaag E. Photohemolytic potency of oral antidiabetic drugs in vitro: effects of antioxidants and a nitrogen atmosphere. Photodermatol Photoimmunol Photomed. 1996 Aug;12(4):166-70. PubMed PMID: 9017793. 16: Lao B, Czyzyk A, Szutowski M, Szczepanik Z. Alcohol tolerance in patients with non-insulin-dependent (type 2) diabetes treated with sulphonylurea derivatives. Arzneimittelforschung. 1994 Jun;44(6):727-34. PubMed PMID: 8053971. 17: Nielsen-Kudsk JE, Thirstrup S. Effects of antidiabetic sulphonylureas, cromakalim and their interaction in guinea-pig isolated tracheal smooth muscle. Pulm Pharmacol. 1993 Sep;6(3):185-92. PubMed PMID: 8219573. 18: Lao B, Czyzyk A, Szutowski M, Szczepanik Z. [Alcohol tolerance in patients with non-insulin-dependent diabetes (type 2) treated orally with drugs--derivatives of sulphonylurea]. Pol Arch Med Wewn. 1993 Jun;89(6):463-79. Polish. PubMed PMID: 8415209. 19: Girardin E, Vial T, Pham E, Evreux JC. [Hypoglycemia induced by oral hypoglycemic agents. Records of the French Regional Pharmacovigilance Centers 1985-1990]. Ann Med Interne (Paris). 1992;143(1):11-7. French. PubMed PMID: 1605454. 20: Nielsen-Kudsk JE, Thirstrup S. Antidiabetic sulfonylureas relax isolated rabbit coronary arteries. Eur J Pharmacol. 1991 Dec 17;209(3):273-5. PubMed PMID: 1797568.